MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc., (NASDAQ: GTXI) announced today that data from the recent Phase II proof of concept clinical trial of Ostarine™ and from the ongoing Phase III clinical trial evaluating ACAPODENE® (toremifene citrate) 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) will be presented at the upcoming 2007 Annual Meeting of the American Society of Clinical Oncology being held June 1 – 5 at McCormick Place in Chicago.
